摘要
目的研究不同剂量去氧孕烯炔雌醇（妈富隆）治疗更年期失调性子宫出血的临床效果。方法临床纳入162例我院2012年8月～2015年8月期间收治的更年期功能失调性子宫出血患者作为研究对象，所有患者人院后给予妈富隆口服进行治疗。按入院顺序随机分为两组各81例。其中81例患者给予妈富隆2片／dVI服治疗作为观察组，服药3d后改为1片／d，21d为一个疗程，连续服用一个疗程。另81例患者给予妈富隆1片，d口服治疗作为对照组，连续服用一个疗程。两组患者撤退性出血后第5天继续口服妈富隆治疗，连续服用两个疗程。随访患者3个月，观察两组患者治疗效果、复发情况、性激素水平、子宫内膜厚度以及不良反应情况。结果观察组治疗总有效率及复发率分别为95．06％、3．70％，明显优于对照组的86．42％、14．81％，差异有统计学意义（P〈0．05）。治疗前两组患者E2、FSH、LH、P水平及子宫内膜厚度均无差异（P〉0．05）；治疗后观察组E2、FSH、LH、P水平及子宫内膜厚度明显小于对照组，差异有统计学意义（P〈0．05）。观察组、对照组不良反应发生率分别为8．64％、9．88％，差异无统计学意义（P〉0．05）。结论妈富隆2片，d治疗更年期功能失调性子宫出血效果显著，明显改善性激素水平，减少子宫内膜厚度，不良反应无明显增加，安全可靠，值得临床应用及推广。
Objective To study the clinical effect of different doses of Marvelon in treatment of dysfunctional uterine bleeding. Methods 162 cases of patients with menopausal dysfunctional uterine bleeding cured in our hospital from August 2012 to August 2015 were selected as the study objects. All the patients were treated with Marvelon after hospital. According to the order of admission, they were randomly divided into two groups with 81 cases in each. Patients in observation group were treated with Marvelon 2/d oral, 3D after taking the drug to 1/d, 21d for a course of treatment, taking a course of treatment continuously. And patients in control group were treated with Marvelon 1/d oral, taking a course of treatment continuously. All the patients in the two groups were treated with oral Marvelon withdrawal bleeding after 5D, taking a course of treatment continuously. Followed up for 3 months, treatment effects, recurrence, sex hormone levels, endometrial thickness, and adverse reactions of the two groups were observed. Results The total effective rate and recurrence rate of observation group were 95.06% and 3.70%, respectively, which were significantly better than those of control group with 86.42% and 14.81%, and the differences were statistically significant （P 〈 0.05）. There were no differences on E2, FSH, LH, P levels and endometrial thickness of patients in the two groups before the treatment, P 〉0.05. E2, FSH, LH, P levels and endometrial thickness of observation group after treatment were significantly less than those of control group, and the differences were statistically significant （P 〈 0.05）. The incidence of adverse reactions in the observation group and control group were 8.64% and 9.88%, respectively, and there was no significant difference （P 〉0.05）. Conclusion The effect of Marvelon 2/d oral in treatment of dysfunctional uterine bleeding is significant. It can significantly improve sex hormone levels, and reduce endometrial thickness with no significant increase in adverse reaction. It is safe and reliable. It is worthy of clinical application and promotion.
出处
《中国医药科学》
2016年第20期76-78,99,共4页
China Medicine And Pharmacy
